Developer docs
API playgroundTry for free, no card

Search company profiles

CytoAgents

Full company profile

uuid00004fg

Namestring
CytoAgents
Legal namestring
CytoAgents, Inc.
Websiteurl
cytoagents.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cytokine release syndrome treatment, immunomodulatory therapeutics, inflammatory disease drugs, CAR T-cell therapy support, prostacyclin analogues
Industry3 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Immunomodulatory Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) and related inflammatory conditions. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.

cytoagents.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CytoAgents develops CTO1681, a novel orally bioavailable steroid-sparing small molecule immunomodulator that selectively targets prostacyclin/prostaglandin receptors to block NF-kB and PGE2 inflammatory signaling pathways. The drug is being advanced through clinical trials for cytokine release syndrome (CRS) and ICANS in CAR T-cell therapy patients, with a pipeline-in-a-pill expansion strategy into pulmonary arterial hypertension, asthma, and atopic dermatitis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CTO1681 was well tolerated at 10μg TID with no serious adverse events reported in Phase 1b/2a clinical trial; trial is now enrolling a higher dose cohort
+2 more records
Product overview1 text field

CytoAgents is advancing CTO1681 (formerly known as GP1681), a novel, orally bioavailable small molecule drug that acts as a steroid-sparing inhibitor of prostaglandin/prostacyclin-mediated inflammation. The company operates a 'pipeline-in-a-pill' strategy, where CTO1681 targets multiple indications including CAR T-cell and TCE therapy-related CRS and ICANS, pulmonary arterial hypertension, asthma, and atopic dermatitis. CTO1681 modulates inflammatory signaling through selective IP, EP4, EP3, and EP1 receptors while sparing EP2 receptor activity, providing a differentiated approach compared to JAK inhibitors.

Product and service1 record
1CTO1681
CategoryImmunomodulatory Biopharmaceutical
Description

CTO1681 is a novel, orally bioavailable steroid-sparing small molecule immunomodulator that selectively targets prostacyclin/prostaglandin receptors (IP, EP4, EP3, EP1 while sparing EP2) to modulate cytokine signaling without impairing normal immune function. It is being developed for prevention and treatment of cytokine release syndrome (CRS) and ICANS in CAR T-cell and bispecific T-cell engager therapy patients, with pipeline expansion into pulmonary arterial hypertension, asthma, and atopic dermatitis.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

First patient enrolled in Phase 1b/2a clinical trial for CRS in CAR T-cell therapy at UPMC Hillman Cancer Center, the largest network of outpatient cancer centers in the tri-state area of Pennsylvania, Ohio, and West Virginia.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-10-01
Description

Contract research organization (CRO) partnership for Phase 1 clinical trial of GP1681 for COVID-19 cytokine storm treatment in Australia.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-10-01
Description

Clinical trial unit partnership for Phase 1 trial of GP1681 for COVID-19 cytokine storm treatment, conducted in Australia as a randomized, double-blind, placebo-controlled study.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-01
Description

Collaboration to accelerate development of lead COVID-19 drug candidate GP1681 into human clinical trials. Quotient provided formulation, manufacturing expertise, and rapid drug product supply for Phase I and II testing.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immunology company developing therapies for inflammatory and autoimmune diseases, including programs addressing CAR T-cell related toxicities. Directly comparable as a small-cap biotech focused on cytokine-driven and inflammatory conditions with multiple pipeline assets.

TypeBroad incumbent
Description

Owns Actemra (tocilizumab), the only FDA-approved therapy for CAR T-cell-induced cytokine release syndrome. Directly competes in the CRS indication but as part of a much broader immunology and oncology portfolio.

TypeDirect peer
Description

Markets Jakafi (ruxolitinib) which is used off-label for steroid-refractory CRS, and is a direct competitor in the inflammation and immunology space. CytoAgents' newly appointed CSO Michael Howell previously contributed to Jakafi's development at Incyte.

TypeEmerging player
Description

Clinical-stage company developing cell therapies and treatments for autoimmune and inflammatory conditions, including programs relevant to CAR T-cell therapy toxicities. Comparable as a smaller emerging player targeting cytokine-driven complications.

TypeEmerging player
Description

Clinical-stage biotechnology company developing inflammation and immunology therapeutics. Comparable in size and stage to CytoAgents with a pipeline of antibody-based inflammatory disease candidates.

TypeDirect peer
Description

Market leader in pulmonary arterial hypertension (PAH) with approved prostacyclin analogues (Tyvaso, Remodulin). CytoAgents' CTO1681 also targets the IP/prostacyclin pathway for PAH, making United Therapeutics a key reference competitor for that indication.

TypeBroad incumbent
Description

Dupixent (dupilumab) is the market-leading biologic for atopic dermatitis and asthma. CytoAgents' CTO1681 targets both indications, making this franchise a key indirect competitor and benchmark for the inflammation pipeline.

TypeBroad incumbent
Description

Rinvoq (upadacitinib) is a leading JAK inhibitor for atopic dermatitis and other inflammatory conditions. CTO1681 explicitly positions itself as a non-JAK alternative, making AbbVie a critical competitive reference point.

TypeBroad incumbent
Description

Developed sotatercept (Winrevair) for PAH, representing a new mechanism in the indication. Acquired by Merck in 2021, it exemplifies the type of large-pharma exit opportunity for successful PAH-focused biotechs like CytoAgents.

TypeEmerging player
Description

Small clinical-stage biotech developing novel small-molecule therapies for immune-mediated diseases. Comparable in size, stage, and therapeutic focus on inflammation-driven conditions.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CytoAgents

Immunomodulatory Biopharmaceuticalscytoagents.com

CytoAgents firmographics

Firmographics
Name
CytoAgents
Legal name
CytoAgents, Inc.
Website
https://cytoagents.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

CytoAgents industry classification

Industry
Product category
Immunomodulatory Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Cytokine release syndrome treatment
  • Immunomodulatory therapeutics
  • Inflammatory disease drugs
  • CAR T-cell therapy support
  • Prostacyclin analogues

Where CytoAgents is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CytoAgents business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotechnology company developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) and related inflammatory conditions. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

CytoAgents product offering

Product offering

Core offering

CytoAgents develops CTO1681, a novel orally bioavailable steroid-sparing small molecule immunomodulator that selectively targets prostacyclin/prostaglandin receptors to block NF-kB and PGE2 inflammatory signaling pathways. The drug is being advanced through clinical trials for cytokine release syndrome (CRS) and ICANS in CAR T-cell therapy patients, with a pipeline-in-a-pill expansion strategy into pulmonary arterial hypertension, asthma, and atopic dermatitis.

Product overview

CytoAgents is advancing CTO1681 (formerly known as GP1681), a novel, orally bioavailable small molecule drug that acts as a steroid-sparing inhibitor of prostaglandin/prostacyclin-mediated inflammation. The company operates a 'pipeline-in-a-pill' strategy, where CTO1681 targets multiple indications including CAR T-cell and TCE therapy-related CRS and ICANS, pulmonary arterial hypertension, asthma, and atopic dermatitis. CTO1681 modulates inflammatory signaling through selective IP, EP4, EP3, and EP1 receptors while sparing EP2 receptor activity, providing a differentiated approach compared to JAK inhibitors.

Differentiator

Problem solved

Functional benefit

Products and services

  • CTO1681 CTO1681 is a novel, orally bioavailable steroid-sparing small molecule immunomodulator that selectively targets prostacyclin/prostaglandin receptors (IP, EP4, EP3, EP1 while sparing EP2) to modulate cytokine signaling without impairing normal immune function. It is being developed for prevention and treatment of cytokine release syndrome (CRS) and ICANS in CAR T-cell and bispecific T-cell engager therapy patients, with pipeline expansion into pulmonary arterial hypertension, asthma, and atopic dermatitis.

Quantifiable outcome

  • CTO1681 was well tolerated at 10μg TID with no serious adverse events reported in Phase 1b/2a clinical trial; trial is now enrolling a higher dose cohort
  • +2 more outcomes

Companies that use CytoAgents

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

CytoAgents technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CytoAgents partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • UPMC Hillman Cancer CentercoreStrategic or Co-development Partner · 1 October 2023First patient enrolled in Phase 1b/2a clinical trial for CRS in CAR T-cell therapy at UPMC Hillman Cancer Center, the largest network of outpatient cancer centers in the tri-state area of Pennsylvania, Ohio, and West Virginia.
  • NovotechminorStrategic or Co-development Partner · 1 October 2020Contract research organization (CRO) partnership for Phase 1 clinical trial of GP1681 for COVID-19 cytokine storm treatment in Australia.
  • CMAX Clinical ResearchminorStrategic or Co-development Partner · 1 October 2020Clinical trial unit partnership for Phase 1 trial of GP1681 for COVID-19 cytokine storm treatment, conducted in Australia as a randomized, double-blind, placebo-controlled study.
  • Quotient SciencescoreStrategic or Co-development Partner · 1 April 2020Collaboration to accelerate development of lead COVID-19 drug candidate GP1681 into human clinical trials. Quotient provided formulation, manufacturing expertise, and rapid drug product supply for Phase I and II testing.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

CytoAgents competitors and assessment

Company assessment

Direct peers

  • Kiniksa Pharmaceuticals: Clinical-stage immunology company developing therapies for inflammatory and autoimmune diseases, including programs addressing CAR T-cell related toxicities. Directly comparable as a small-cap biotech focused on cytokine-driven and inflammatory conditions with multiple pipeline assets.
  • Incyte Corporation: Markets Jakafi (ruxolitinib) which is used off-label for steroid-refractory CRS, and is a direct competitor in the inflammation and immunology space. CytoAgents' newly appointed CSO Michael Howell previously contributed to Jakafi's development at Incyte.
  • United Therapeutics: Market leader in pulmonary arterial hypertension (PAH) with approved prostacyclin analogues (Tyvaso, Remodulin). CytoAgents' CTO1681 also targets the IP/prostacyclin pathway for PAH, making United Therapeutics a key reference competitor for that indication.

Broad incumbents

  • Roche (Genentech): Owns Actemra (tocilizumab), the only FDA-approved therapy for CAR T-cell-induced cytokine release syndrome. Directly competes in the CRS indication but as part of a much broader immunology and oncology portfolio.
  • Regeneron / Sanofi (Dupixent): Dupixent (dupilumab) is the market-leading biologic for atopic dermatitis and asthma. CytoAgents' CTO1681 targets both indications, making this franchise a key indirect competitor and benchmark for the inflammation pipeline.
  • AbbVie (Rinvoq): Rinvoq (upadacitinib) is a leading JAK inhibitor for atopic dermatitis and other inflammatory conditions. CTO1681 explicitly positions itself as a non-JAK alternative, making AbbVie a critical competitive reference point.
  • Acceleron Pharma (Merck): Developed sotatercept (Winrevair) for PAH, representing a new mechanism in the indication. Acquired by Merck in 2021, it exemplifies the type of large-pharma exit opportunity for successful PAH-focused biotechs like CytoAgents.

Emerging players

  • Cartesian Therapeutics: Clinical-stage company developing cell therapies and treatments for autoimmune and inflammatory conditions, including programs relevant to CAR T-cell therapy toxicities. Comparable as a smaller emerging player targeting cytokine-driven complications.
  • AnaptysBio: Clinical-stage biotechnology company developing inflammation and immunology therapeutics. Comparable in size and stage to CytoAgents with a pipeline of antibody-based inflammatory disease candidates.
  • Aldeyra Therapeutics: Small clinical-stage biotech developing novel small-molecule therapies for immune-mediated diseases. Comparable in size, stage, and therapeutic focus on inflammation-driven conditions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

CytoAgents social profiles

Digital presence

CytoAgents financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CytoAgents leadership team

Management profile

Number of profiles

Profiles5 records

CytoAgents funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CytoAgents M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CytoAgents

What does CytoAgents do?

CytoAgents develops CTO1681, a novel orally bioavailable steroid-sparing small molecule immunomodulator that selectively targets prostacyclin/prostaglandin receptors to block NF-kB and PGE2 inflammatory signaling pathways. The drug is being advanced through clinical trials for cytokine release syndrome (CRS) and ICANS in CAR T-cell therapy patients, with a pipeline-in-a-pill expansion strategy into pulmonary arterial hypertension, asthma, and atopic dermatitis.

Is CytoAgents a public or private company?

CytoAgents is a private company. It is classified as venture growth investor backed and is currently operating.

When was CytoAgents founded?

CytoAgents was founded in 2018. It employs 1 to 10 people.

Where is CytoAgents based?

CytoAgents is headquartered in Pittsburgh, United States, in the North America region.

How does CytoAgents make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are CytoAgents's main competitors?

Direct peers on record are Kiniksa Pharmaceuticals, Incyte Corporation and United Therapeutics. Broad incumbents are Roche (Genentech), Regeneron / Sanofi (Dupixent), AbbVie (Rinvoq) and Acceleron Pharma (Merck). Emerging players are Cartesian Therapeutics, AnaptysBio and Aldeyra Therapeutics.

Does CytoAgents have an API?

No public API is recorded for CytoAgents.

What industry is CytoAgents in?

CytoAgents's product category is Immunomodulatory Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCytoAgents Presents New Preclinical CTO1681 Data at the 2026 EADV CongressCytoAgents presented new preclinical data on CTO1681 at the 2026 EADV Congress in Vienna, showing suppression of proinflammatory cytokines in atopic dermatitis models. The data report that CTO1681 significantly reduced production of 21 of 29 cytokines and chemokines, including IL-4, IL-5, IL-13, IL-17, TNF-α, IL-1β, and IFN-γ, supporting its development as an oral immunomodulator.Business Wire BlogCytoAgents Expands Scientific Advisory Board Appointing Dr. Michael Wechsler and Dr. Johann Gudjonsson to Guide Pipeline ExpansionCytoAgents added Dr. Michael Wechsler and Dr. Johann Gudjonsson to its Scientific Advisory Board to guide pipeline expansion. The company's lead program, CTO1681, is an oral steroid-sparing immunomodulator targeting upstream immune activation pathways. The appointments aim to accelerate development for immune-mediated diseases.PharmiWeb.comCytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific OfficerCytoAgents, Inc., a clinical-stage biotechnology company, announced the appointments of Dr. Johannes Wolff as Chief Medical Officer and Michael D. Howell as Chief Scientific Officer. Both executives bring extensive pharmaceutical industry experience, with Dr. Wolff having held senior roles at Replimune, AbbVie, and Novartis, and Howell having served as CSO at Zura Bio and DermTech while also working at Incyte and AstraZeneca/MedImmune. The company stated these appointments will support advancement of its lead drug candidate CTO1681, currently in Phase 1b/2a trials for oncology patients receiving CAR T-Cell Therapy, with plans to expand into asthma, COPD, and atopic dermatitis.Business Wire BlogCytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific OfficerCytoAgents, a Pittsburgh-based clinical-stage biotechnology company developing CTO1681, announced the appointment of Dr. Johannes Wolff as Chief Medical Officer and Michael D. Howell as Chief Scientific Officer. Dr. Wolff brings over three decades of experience including roles at Replimune, AbbVie, and Novartis, while Howell has over 25 years in research and drug development at companies including Zura Bio, DermTech, Incyte, and AstraZeneca/MedImmune. The company stated these appointments will support advancement of its CTO1681 pipeline, currently in Phase 1b/2a trials for oncology patients receiving CAR T-Cell Therapy.PharmiWeb.comCytoAgents to Present New CTO1681 Data at the ESMO Immuno-Oncology Congress 2025CytoAgents, Inc., a clinical-stage biotechnology company headquartered in Pittsburgh, announced it will present data from two Investigational New Drug application-enabling studies for its drug candidate CTO1681 at the ESMO Immuno-Oncology Congress 2025 in London on December 10-12, 2025. The studies demonstrate that CTO1681, an oral immune modulator targeting prostaglandin-mediated inflammation, reduces cytokine release syndrome in CAR T-Cell therapy patients without compromising the therapy's anti-tumor efficacy. The company is currently enrolling patients in a Phase 1b/2a clinical trial evaluating CTO1681 in lymphoma patients receiving CAR T-Cell Therapy.PharmiWeb.comCytoAgents Announces Poster Presentation of New CTO1681 Clinical Data at the 67th American Society of Hematology Annual MeetingCytoAgents, a clinical-stage biotechnology company, announced that preliminary safety data from its Phase 1b/2a clinical trial for lead drug candidate CTO1681 will be presented at the 67th American Society of Hematology Annual Meeting in December 2025. The trial data showed CTO1681 was well tolerated at the 10μg three times daily dose with no dose-limiting toxicities or drug-related serious adverse events observed in the first patient cohort. Based on these positive findings, CytoAgents is now enrolling the second cohort at an escalated dosage of 20μg TID.Business Wire BlogCytoAgents Receives Fourth Grant From National Institutes of Health to Advance Research on Cytokine Release SyndromeCytoAgents, a Pittsburgh-based clinical-stage biotechnology company, has been awarded a $2.25 million National Institutes of Health grant through the National Cancer Institute, marking the fourth NIH grant the company has received in five years with total funding reaching $7.85 million. The funding will support expansion of clinical trials for CTO1681, the company's lead investigational drug candidate designed to prevent and mitigate cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in multiple myeloma patients receiving CAR T-Cell therapy. CytoAgents is currently enrolling patients in a Phase 1b/2a clinical trial evaluating CTO1681 in lymphoma patients at multiple U.S. sites, with plans to broaden the patient population and pursue a universal preventative therapy for these treatment-related complications.LinkedInCytoAgents reaches FDA milestone and closes on $7 million funding round led by PCG CapitalCytoAgents secured $7 million in Series A2 funding led by PCG Capital and received a 'Study May Proceed' letter from the FDA for its lead compound CTO1681. This regulatory clearance allows the biotechnology firm to advance clinical trials for a potential breakthrough therapy targeting Cytokine Release Syndrome in the U.S.